Clinical ResearchPulmonary Vascular DiseaseFavorable Effects of Inhaled Treprostinil in Severe Pulmonary Hypertension: Results From Randomized Controlled Pilot Studies
Abbreviations and Acronyms
Cited by (0)
This work was financially supported by Lung RX Inc., Satellite Beach, Florida. Dr. Bruce H. Brundage acted as the guest editor for this paper.
- 1
Drs. Gessler and Schmehl are holders of a patent of the technology of the IloNeb ultrasonic nebulization device.
- 2
Dr. Ghofrani received grant and contract support from Pfizer Ltd., Altana Pharma AG, Schering AG, and served on the advisory board of Pfizer Ltd.
- 3
Dr. Grimminger received grant and contract support from Pfizer Ltd. and Altana Pharma AG.
- 4
Dr. Rubin received research grants from the NIH and industry-sponsored grants; served as a consultant for Actelion, United Therapeutics, Pfizer, Myogen, Schering, Nitrox, MondoBiotech, and CoTherix; and received stock options in United Therapeutics for service on the Scientific Advisory Board.
- 5
Dr. Seeger received grant and contract support from Schering, Altana Pharma, Myogen Inc. Westminster, LungRX, and Aventis Pharma.
- 6
Dr. Olschewski was a consultant and investigator for ScheringAG, LungRX, CoTherix, Encysive, and Myogen; received research grants from ScheringAG and LungRX; received treprostinil from Lung RX and inhalation devices from nebu-tec; and used iloprost, sildenafil, and treprostinil off-label for treatment of pulmonary hypertension.